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Objective. To determine if gestational age of prior preterm delivery inﬂuences a woman’s receipt of 17-hydroxyprogesterone
caproate(17-OHP-C).Methods.Retrospectivecohortofwomeneligiblefor17-OHP-CatDukeObstetricsClinicwereidentiﬁedby
medical record review. Sociodemographic and clinical characteristics were abstracted. Results. Of 104 eligible subjects, 82 (78.8%)
were oﬀered 17-OHP-C. Of these, thirty-four (41.5%) declined. The median gestational age of the most recent preterm delivery
was signiﬁcantly lower among subjects who accepted 17-OHP-C as compared to those who declined (28.7 vs. 34.0 weeks, P = .02)
a n di ns u b j e c t so ﬀered 17-OHP-C compared to those not oﬀered 17-OHP-C (30.2 vs. 36.0 weeks, P = .03). Subjects not oﬀered
17-OHP-C were more likely to have had an interval term delivery (31.8% vs. 9.7%, P = .009) Conclusion. Women with earlier
preterm deliveries were more likely to be oﬀered and accept 17-OHP-C. Prior obstetric history may inﬂuence both providers’ and
patients’ willingness to discuss and/or accept 17-OHP-C.
1.Introduction
Preterm birth, deﬁned as delivery prior to 37-week gestation,
is the second leading cause of infant mortality in the United
States after congenital malformations [1]. The incidence of
preterm delivery continues to increase in this country such
that it now exceeds 12% of all births [2]. The total national
cost of care for premature babies is in excess of $13.6 billion
annually [3]. Among survivors, the prevalence of both short,
and long-term morbidities, including respiratory disease,
neurodevelopmental problems, and gastrointestinal disease,
is estimated to be as high as 60% [4].
The true cost of prematurity is only beginning to be
understood. A recent study by Swamy et al. found dimin-
ished long-term survival and reproduction rates among
individuals born prematurely in Norway between 1967 and
1988 [5]. It is becoming clear that, even if preterm infants
surpassimmediateobstacles,theiroveralllong-termhealthis
diminished. Despite extensive research in this ﬁeld, the rate
of preterm birth in the United States has increased over 20%
in the past 20 years [2].
Recent randomized control trials have evaluated the
role of 17-hydroxyprogesterone caproate (17-OHP-C) and
progesterone gel or suppositories in the prevention of
recurrentpreterm birth[6–8].Resultsfromtwotrialssuggest
that administration of progestin to women at high-risk for
preterm birth may decrease the recurrence risk by up to
35% [6, 7]. A more recent trial of progesterone vaginal gel
versus placebo was not able to demonstrate a diﬀerence in
the frequency of recurrent preterm birth ≤32 weeks in a
high risk group of women [8]. The American College of
Obstetricians and Gynecologists recommends that women at
risk for recurrent preterm birth be considered candidates for
progestin supplementation [9].
In a randomized trial of 17-OHP-C, Meis et al. found
a preterm delivery rate with placebo of 55% much higher
thanthe37%thatwasoriginallypredicted[7].Oneproposed
explanation for this ﬁnding was that the subjects enrolled in2 Journal of Pregnancy
the trial might have been at particularly high risk for preterm
delivery and not necessarily representative of the general
population of women considered eligible for 17-OHP-C.
Perhaps women with histories of earlier preterm deliveries
would be more likely to enroll in a trial of progesterone.
The primary objective in this study was to determine
if gestational age of a prior preterm delivery inﬂuences
providers’ decisions to oﬀer and patients’ decisions to accept
17-hydroxyprogesterone caproate in the current gestation.
2.MaterialsandMethods
We conducted a retrospective cohort study of women eligible
for 17-OHP-C at the Duke University Outpatient Obstetrics
Clinic from January 2007 through June 2008. Approval was
obtained from the Duke University Institutional Review
Board. Subjects were identiﬁed by searching two indepen-
dent obstetrics electronic clinical databases, and data were
collected by chart abstraction.
All included subjects were pregnant and had a docu-
mented prior spontaneous, singleton preterm delivery due
to either preterm labor or preterm premature rupture of
membranes of less than 37 but more than 20-week gestation.
Women with a multifetal gestation in the current pregnancy
or with prior indicated preterm delivery were excluded
from this analysis. Demographic and clinical characteristics
collected include prior obstetric history, marital status, race,
socioeconomic variables, pregnancy complications (preterm
labor, gestational diabetes, abruption, antepartum bleeding,
oligohydramnios, preeclampsia, gestational hypertension, or
cerclage placement), pregnancy outcome, delivery route,
chorioamnionitis, and indication for delivery. Neonatal
outcomes collected included birth weight, sex, one- and ﬁve-
minute APGAR scores, and congenital anomalies. If inter-
mediate or intensive care was required, any further neonatal
complications were recorded. The protocol at our institution
is for the nurses to screen for 17-OHP-C eligibility and for
the provider to enter into the electronic medical record if 17-
OHP-C is oﬀered. Patients with a prior history of indicated
preterm delivery (such as for preeclampsia) were not eligible
for 17-OHP-C at our institution and thus not included
in this analysis. At our instituation, 17-OHP-C is started
between 16/0 and 21/6 weeks and continues weekly until
34 weeks of gestation. We do not have a standard method
for assessing compliance with progesterone therapy. Results
were analyzed using t-test or Mann-Whitney for continuous
variables and Fisher’s exact test for categorical variables
(Analyse-It, England, UK). For our primary objective, there
were no missing data. Among the entire cohort, delivery data
was unavailable for four patients (3.8%).
3. Results
Between January 2007 and June 2008, 104 subjects met
eligibility criteria for 17-OHP-C. During the study period,
approximately 1100 obstetrical patients were cared for in our
clinical practice by twenty providers. Of the 104 eligible sub-
jects, 82 (78.8%) were oﬀered 17-OHP-C. Table 1 describes
the demographic and clinical characteristics of women
eligible for 17-OHP-C. Those women oﬀered 17-OHP-C
were signiﬁcantly younger and less educated than those
women not oﬀered17-OHP-C, butotherwise thetwogroups
did not diﬀer in demographic or clinical characteristics.
Among subjects eligible for 17-OHP-C, the median
gestational age of the most recent preterm delivery was sig-
niﬁcantly lower for subjects oﬀered 17-OHP-C as compared
to those who were not oﬀered 17-OHP-C (30.2 vs. 36.0
weeks, P = .03). In addition, subjects not oﬀered 17-OHP-
C were more likely to have had an interval term delivery,
deﬁned as a term delivery occurring after the index preterm
delivery that qualiﬁed them for 17-OHP-C (31.8% vs. 9.7%,
P = .009).
Table 2 describes the characteristics of women who were
oﬀered 17-OHP-C. Of the 82 subjects oﬀered 17-OHP-C,
48 (58.5%) accepted treatment. Subjects that accepted 17-
OHP-C had a lower median gestational age in their most
recent delivery as compared to those who declined (28.7 vs.
34.0 weeks, P = .02). The median gestational age of the
earliest preterm delivery (that with the lowest gestational
age) was also lower among subjects that accepted 17-OHP-C
as compared to those who declined although this did not
reach statistical signiﬁcance (28.0 vs. 32.0 weeks, P = .11).
In addition, subjects who declined 17-OHP-C tended to be
morelikelytohavehadanintervaltermdeliveryascompared
to those who accepted (17.6% vs. 4.2%, P = .10). There
was no signiﬁcant diﬀerence in the median gestational age
at delivery in the current gestation between subjects who
received 17-OHP-C as compared to those who did not (37.0
vs. 37.2 weeks, P = .39).
4. Discussion
Our primary objective was to determine if gestational age
at a prior preterm delivery impacts a provider decision to
oﬀer and/or a patient decision to accept 17-OHP-C. In this
study, the median gestational age of the most recent preterm
delivery was 6 weeks earlier in subjects oﬀered 17-OHP-C as
compared to those not oﬀered 17-OHP-C and over 5 weeks
earlier in subjects who accepted 17-OHP-C as compared to
those who declined. These ﬁndings suggest that a woman
pregnancy history seems to inﬂuence both providers and
patients oﬀered 17-OHP-C and whether the treatment is
accepted.
Despite the current enthusiasm for 17-hydroxypro-
gesterone caproate, few randomized trials have compared
intramuscular progesterone or progestin to placebo for the
prevention of preterm birth [7, 10–12]. In 1975, Johnson
et al. provided some of the ﬁrst evidence of an eﬀect of 17-
OHP-C on the prevention of recurrent preterm birth [11].
In 2003, Meis et al. found a reduction in the risk of preterm
birth less than 37 weeks with the use of intramuscular 17-
OHP-C among women at high risk for preterm delivery, but
there was an unexpectedly high rate of preterm delivery in
the place boarm [7]. This led to speculation that women
enrolled in this trial were in some way at higher risk
for recurrent preterm delivery than an average cohort of
women with a history of preterm delivery. More complete
demographics and pregnancy history of the patient groupJournal of Pregnancy 3
Table 1: Demographic and clinical characteristics of subjects eligible for 17- Hydroxyprogesterone caproate (17-OHP-C).
Patient characteristic Oﬀered 17-OHP-C
(n = 82)
Not oﬀered 17-OHP-C
(n = 22) P value
Maternal age (mean years ± SD) 27.6 ±5.2 31.7 ± 6.3 .002
% African-American 59.7 (49/82) 72.7 (16/22) .26
% Single 63.4 (52/82) 59.1 (13/22) .71
% Medicaid insurance 73.2 (60/82) 54.5 (12/22) .09
Years of school ≤12 64.4 (47/73) 40.9 (9/22) .04
Preeclampsia or gestational hypertension 17.5 (14/80) 27.3 (6/22) .31
Cerclage (all types) 12.3 (10/81) 9.1 (2/22) 1.00
Multiple (>1) prior preterm birth 39.0 (32/82) 27.3 (6/22) .31
Etiology of index preterm birth due to preterm labor 58.0 (47/81) 59.1 (13/22) .93
Interval term delivery since preterm birth 9.7 (8/82) 31.8 (7/22) .009
Cesarean section (current pregnancy) 25.6 (20/78) 9.1 (2/22) .14
Birth weight (mean gm ± SD) 2662.9 ±744 2653.6 ±923 .96
Gestational age of most recent preterm delivery∗ 30.2 (26.0–34.4) 36.0 (27.5–38.0) .03
Gestational age of earliest preterm delivery∗ 29.2 (25.0–33.0) 31.5 (24.9–36.0) .20
Gestational age at delivery of current gestation∗ 37.0 (35.2–39.1) 37.9 (36.5–39.0) .87
∗Data presented as median and IQR.
Table 2: Demographic and clinical characteristics of subjects oﬀered 17-Hydroxyprogesterone caproate (17-OHP-C).
Patient characteristic Received 17-OHP-C Declined 17-OHP-C P value
(n = 48) (n = 34)
Maternal age (mean years ± SD) 27.7 ± 4.8 27.5 ± 5.8 .87
% African-American 54.2 (26/48) 67.6 (23/34) .22
% Single 64.6 (31/48) 61.8 (21/34) .79
% Medicaid Insurance 77.1 (37/48) 67.6 (23/34) .34
% Years school ≤12 60.4 (26/43) 70.0 (21/30) .40
% Preeclampsia or gestational hypertension (current
pregnancy) 19.6 (9/46) 14.7 (5/34) .76
% Cerclage (all types) 12.7 (6/47) 11.7 (4/34) 1.00
Multiple (>1) prior PTB 37.5 (18/48) 41.2 (14/34) .74
Etiology of index preterm birth due to preterm labor 55.3 (26/47) 61.8 (21/34) .56
Interval term delivery since preterm birth 4.2 (2/48) 17.6 (6/34) .10
Cesarean section (current pregnancy) 28.3 (13/46) 21.9 (7/32) .53
Birth weight (mean gm ± SD) 2571 ±836 2595 ±558 .47
Gestational age of most recent preterm delivery∗ 28.7 (25.3–32.8) 34.0 (28.3–36.0) .02
Gestational age of earliest preterm delivery∗ 28.0 (24.3–32.0)∗ 32.0 (25.2–34.0)∗ .11
Gestational age at delivery of current gestation∗ 37.0 (35.2–38.4)∗ 37.2 (35.2–39.2)∗ .39
∗Data presented as median and IQR.
who refused randomization could help clarify the external
validity of the Meis trial.
A more recent randomized trial by O
 Brien investigated
vaginal progesterone for the prevention of preterm birth in
a group of 659 women. This large study failed to ﬁnd a
diﬀerence between the placebo and study groups [8]. This
was in contrast to an earlier trial by da Fonseca showing a
decrease in preterm birth rate from 28.5% to 13.8% in the
vaginal progesterone group versus placebo [6].
The purpose of our investigation was to examine the
population of women potentially eligible for 17-OHP-C at
ouracademicinstitution.Inourclinicalpractice,thereseems
to be a subset of higher-risk women that are preferentially
oﬀered and more likely to accept 17-OHP-C. We believe
our study population is representative of the population
of women with prior preterm deliveries seen in many
academic practices. As this population is predominantly
single, African-American and on Medicaid, we believe this
is a population of women at high risk for recurrent preterm
birth. Compared to other studies, we had fairly broad
inclusion criteria, which makes our study more generalizable
to diﬀerent populations. As with any retrospective study,
our study is limited only to the patients captured via our
medical record search. In addition, our study is not designed4 Journal of Pregnancy
to evaluate the eﬃcacy of 17-OHP-C. Other potential
weaknesses include patient reporting bias on gestational
age at prior preterm delivery. It is also possible that some
patients were actually oﬀered 17-OHP-C, but this was not
documented. We did not assess for patient compliance
with 17-OHP-C, which may be important in determining
pregnancy outcomes.
The limited rate of 17-OHP-C utilization in our institu-
tion could have many etiologies. These could include system
errors in implementation of 17-OHP-C for appropriate
patients. However, a reliable system already exists at our
institution for indentifying potential candidates. Rather, the
low utilization among this population more likely relates
to either patient perception of the utility or risks of the
drug and/or disagreement with the recommendations on
drug implementation among providers. This study did not
evaluate patient or provider motivations for drug utilization.
Future research eﬀorts are needed to determine the eﬀect
of patient and provider biases on the overall eﬃcacy of 17-
OHP-C. Studies could be directed at determining if there is a
speciﬁc clinical phenotype that would beneﬁt most from 17-
OHP-C. Results in the literature are still mixed. In our study,
17-OHP-C was not commonly oﬀered to women with a
history of late preterm delivery. However, emerging evidence
suggests that late preterm delivery causes greater morbidity
than previously thought [13–15]. Although many providers
do not oﬀer 17-OHP-C to this group of women, it will be
important not only to evaluate the eﬀectiveness of 17-OHP-
C in preventing recurrent preterm birth, but also to evaluate
for a reduction of neonatal morbidity. Until these results
are available, there will likely continue to be a bias among
providers and patients with regards to oﬀering and accepting
progesterone supplementation.
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